MA55497A - Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires - Google Patents

Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires

Info

Publication number
MA55497A
MA55497A MA055497A MA55497A MA55497A MA 55497 A MA55497 A MA 55497A MA 055497 A MA055497 A MA 055497A MA 55497 A MA55497 A MA 55497A MA 55497 A MA55497 A MA 55497A
Authority
MA
Morocco
Prior art keywords
treatment
pharmaceutical compositions
novel compounds
inflammatory disorders
disorders
Prior art date
Application number
MA055497A
Other languages
English (en)
Inventor
Rhalid Akkari
Reginald Christophe Xavier Brys
Hélène Marie Jary
Marijana Komac
Oscar Mammoliti
Mislav Orsulic
Denana Vrban
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA55497A publication Critical patent/MA55497A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055497A 2019-03-29 2020-03-24 Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires MA55497A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1904373.6A GB201904373D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
MA55497A true MA55497A (fr) 2022-02-09

Family

ID=66442982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055497A MA55497A (fr) 2019-03-29 2020-03-24 Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires

Country Status (18)

Country Link
US (1) US20220218679A1 (fr)
EP (1) EP3947378B1 (fr)
JP (1) JP2022526364A (fr)
KR (1) KR20210145238A (fr)
CN (1) CN113646305A (fr)
AR (1) AR118521A1 (fr)
AU (1) AU2020252038A1 (fr)
BR (1) BR112021019055A2 (fr)
CA (1) CA3134736A1 (fr)
CO (1) CO2021014223A2 (fr)
GB (1) GB201904373D0 (fr)
IL (1) IL286677A (fr)
MA (1) MA55497A (fr)
MX (1) MX2021011576A (fr)
PH (1) PH12021552375A1 (fr)
SG (1) SG11202110644WA (fr)
TW (1) TW202102501A (fr)
WO (1) WO2020200900A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN113243338A (zh) * 2021-05-14 2021-08-13 福州大学 一种小鼠缺血性卒中模型的构建与评估方法
CN118530221A (zh) 2021-12-23 2024-08-23 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
CN121464131A (zh) * 2022-12-21 2026-02-03 深蓝治疗有限公司 Mllt1和mllt3抑制剂化合物
EP4389747A1 (fr) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Composés imidazo[1,2-a]pyridiniques et imidazo[1,2-a]pyraziniques en tant qu'inhibiteurs de mllt1 et mllt3
CN119751445B (zh) * 2024-12-10 2025-11-25 江南大学 6-乙炔基吡唑并[1,5-a]吡啶的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418965C (zh) * 2003-08-15 2008-09-17 万有制药株式会社 咪唑并吡啶衍生物
EP1748048A4 (fr) * 2004-05-10 2010-05-26 Banyu Pharma Co Ltd Composé imidazopyridine
EP2688872A4 (fr) * 2011-03-22 2014-08-27 Merck Sharp & Dohme Inhibiteurs de kinases associées aux récepteurs d'interleukine à base d'amidopyrazole
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK1249509A1 (zh) * 2015-07-15 2018-11-02 Aurigene Discovery Technologies Limited 作为irak-4抑制剂的吲唑及氮杂吲唑化合物
GB201518456D0 (en) * 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2018060174A1 (fr) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Benzimidazoles substitués, préparations pharmaceutiques les contenant et leur utilisation pour la production de médicaments
WO2018060072A1 (fr) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Nouveaux benzimidazoles substitués, leur procédé de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la production de médicaments
WO2018083085A1 (fr) * 2016-11-02 2018-05-11 F. Hoffmann-La Roche Ag Dérivés pyrazolo [1,5a]pyrimidine en tant que modulateurs d'irak 4
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
JP7576552B2 (ja) * 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
SG11202110644WA (en) 2021-10-28
GB201904373D0 (en) 2019-05-15
CN113646305A (zh) 2021-11-12
CO2021014223A2 (es) 2021-11-19
WO2020200900A1 (fr) 2020-10-08
EP3947378B1 (fr) 2024-11-13
EP3947378A1 (fr) 2022-02-09
AU2020252038A1 (en) 2021-11-25
KR20210145238A (ko) 2021-12-01
AR118521A1 (es) 2021-10-20
IL286677A (en) 2021-10-31
TW202102501A (zh) 2021-01-16
US20220218679A1 (en) 2022-07-14
CA3134736A1 (fr) 2020-10-08
BR112021019055A2 (pt) 2021-11-30
PH12021552375A1 (en) 2022-09-19
MX2021011576A (es) 2021-10-13
JP2022526364A (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
MA55497A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA51739A (fr) Compositions pharmaceutiques pour le traitement de la fibrose kystique
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3890747A4 (fr) Compositions pour le traitement de la fibrose et de l'inflammation
EP3941462A4 (fr) Composés pharmaceutiques pour le traitement de troubles médiés par le complément
EP3841086A4 (fr) Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
EP3774743C0 (fr) Composés de type promédicaments activés par akr1c3 et leur utilisation pour le traitement de troubles hyperprolifératifs
EP3938340A4 (fr) Dérivés aromatiques hétérobicycliques et hétéroaromatiques pour le traitement de troubles liés à la ferroptose
EP3927705A4 (fr) Composés d'imidazopyridinyle et leur utilisation pour le traitement de troubles neurodégénératifs
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
MA52118A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP4216946A4 (fr) Composés pharmaceutiques pour le traitement de troubles à médiation par complément
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
EP4081201A4 (fr) Composition pharmaceutique pour le traitement ou la prévention de nombreux troubles inflammatoires
EP4121111A4 (fr) Méthodes et compositions pour le traitement de troubles inflammatoires et pulmonaires fibrotiques
IL286688A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
GB201911868D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MA55752A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies